Neuroprotection

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS

Retrieved on: 
Tuesday, April 2, 2024
Neuroprotection, Risk, Stroke, FSVS, NPS, Workflow, Stenosis, FACS, SILK, Blood, Physician, TCAR

SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.

Key Points: 
  • SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.
  • This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the TCAR procedure.
  • “With the launch of the NPS PLUS, we're thrilled to empower our TCAR-trained physicians with a solution that addresses their insights and feedback to further strengthen and streamline the TCAR procedure,” shared Chas McKhann, Chief Executive Officer of Silk Road Medical.
  • During TCAR, the surgical team inserts a tube-like sheath into the carotid artery and connects it to the ENROUTE Neuroprotection System, which temporarily reverses blood flow.

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Retrieved on: 
Tuesday, March 26, 2024
Neuroprotection, OhioHealth, VIVA, LINC, EPS, Stroke, NSPR, Carotid artery stenosis, Clinical trial, PMA, ITT, TEL

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.

Key Points: 
  • TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.
  • Chris Metzger, M.D., System Vascular Chief at Ohio Health, and lead investigator of the C-Guardians trial
    Marvin Slosman, chief executive officer of InspireMD, stated, “At last year’s VIVA and VEITH conferences in November, Dr. Metzger, principal investigator for the C-GUARDIANS trial, presented positive 30-day follow-up data from the trial which demonstrated a DSMI1 rate of just 0.95% in the Intent-To-Treat (ITT) analysis population, and 0.63% in the per-protocol (PP) analysis population.
  • We are very excited to announce today that an abstract of the 12-month outcomes data from this important trial has been accepted for presentation at the upcoming LINC 2024 conference, which is among the most influential and widely attended meetings focused on vascular intervention.
  • We are optimistic that the results will show a similar level of neuroprotection, which may support a Premarket Approval Application (PMA) later this year and allow us to prepare for a commercial launch of CGuard Prime in the U.S. in the first half of 2025, if approved.”

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Retrieved on: 
Tuesday, April 9, 2024
Neurology, Neuroprotection, Element, Conference call, Institutional review board, Cerebrospinal fluid, Survival, Disease, ALS, SPA, Bone marrow, CSF, Data monitoring committee, Webcast, Patient, Protocol, Biomarker, Mortality, Microsoft Exchange Server, Stem cell, DMC, Screening, Agency, Safety, CAFS, Brainstorm, Therapy, Marketing, FDA, BLA, Neuroinflammation, Food, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). 

Key Points: 
  • (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
  • The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.
  • We appreciate the Agency's engagement and guidance during the SPA process and look forward to moving forward with the study."
  • The Phase 3b trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS.

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle

Retrieved on: 
Monday, April 1, 2024
Research, Neuroprotection, Sf9, Glaucoma, ARVO, HEK293, HEK 293 cells

HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Key Points: 
  • HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.
  • ARVO is the largest international society dedicated to ophthalmology and vision-related topics.
  • Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer, is invited to present "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells", at the 2024 ARVO Symposium on "Developing gene therapy for glaucoma neuroprotection: Opportunities and challenges", May 9, 8 – 10 am.
  • In addition to the invited talk, there will be two more scientific presentations from Avirmax Biopharma and an exhibitor booth #1604 to showcase the latest progress and data package:

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Neuroprotection, Research, Conference, Prejudice, Disease, SPA, ALS, Patient, Biomarker, Committee, Gene, MD, Biologics license application, Agency, Safety, Brainstorm, Poster, Therapy, Marketing, FDA, BLA, Episcopal conference, Food, Pharmaceutical industry

NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
  • We continue to believe that, if approved, NurOwn has the potential to be a valuable treatment option for ALS patients in need.
  • Stacy Lindborg, Ph.D., co-CEO BrainStorm commented, "We are acutely aware of the challenges faced by those afflicted with ALS.
  • In October 2023, Brainstorm announced a strategic realignment to enable accelerated development of NurOwn for the treatment of ALS.

Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease

Retrieved on: 
Tuesday, February 27, 2024
Molecule, Glucocerebrosidase, DSM-IV codes, Neuroprotection, Doctor of Philosophy, Conference

CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.

Key Points: 
  • CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.
  • “We created Vanqua Bio with the aim of developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including GBA-PD, which is the largest genetically defined subset of Parkinson’s disease,” said Jim Sullivan, PhD, Co-founder and Chief Executive Officer of Vanqua Bio.
  • “We look forward to discussing the pre-clinical characterization of our clinical stage program, VQ-101, a brain-penetrant small molecule allosteric activator of GCase.
  • Furthermore, we look forward to sharing data on the development of a live cell GCase activity assay, which has enabled measurement of GCase activation in our preclinical systems and will be used to assess GCase activation in our Phase 1 trial.”
    Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust In-Vivo Target Engagement

Red light therapy for neuro/cognitive benefits

Retrieved on: 
Friday, February 23, 2024
Emotion, Neuroscience, Journal of Neuroscience Research, Neuron, Amnesia, Growth, Swelling, TBI, Perception, Attention, Mammal, Circadian rhythm, Diagnosis, PBM, Sunlight, Head, Traumatic brain injury, Stroke, DSM-IV codes, Memory, Light, Immunity, Brain, Anxiety, Randomized controlled trial, Sleep, Radical, Learning, Parkinson's disease, RLT, Oxidative stress, Glucose, Potential, LLLT, Research, Human, LED, BBA, System, Dicarboxylic acid, Inflammation, Neuroprotection, FDA, Sensation, Ageing, Thought, Cell, Brain damage, Nutrient, Patient, Cognition, Dementia, Antioxidant, Medical imaging

There is a simple and practical way – red light therapy to improve your brain function.

Key Points: 
  • There is a simple and practical way – red light therapy to improve your brain function.
  • Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
  • Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
  • Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024
ACT, ERP, Central nervous system, Dementia, Excitotoxicity, ALS, Research, MNDA, Pathology, Research and development, Inflammation, HGF, Conference, Society, Annual general meeting, Doctor of Philosophy, Frontiers, Biomarker, Administration, Clinical trial, Survival, Investment, Neuroprotection, Three-body problem, G&A, Athira Pharma, Lewy body, Insurance, Pharmaceutical industry

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Cepham Introduces Senolytics Inspired by Ayurveda and TCM for Sustainable Aging

Retrieved on: 
Tuesday, February 20, 2024
Ageing, Regeneration, Inflammation, Senolytic, Neuroprotection, Human, Overalls, Traditional Chinese medicine, Cell, Rasayana, Health, Safety, TCM, Notifiable disease, Longevity, Science, Autophagy, Research, DNA, Pharmaceutical industry

SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.

Key Points: 
  • SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.
  • “Cepham’s decision to include senolytics in its Sustainable Aging ingredient offerings reflects our company's commitment to delivering affordable, high-quality, evidence-based, and safe ingredients to customers,” says Christopher Lamb , vice president of commercial strategy at Cepham.
  • The expansion of senolytics in Cepham’s Sustainable Aging product line marks a pivotal moment in the evolution of longevity solutions.
  • For more information about Cepham, Inc. and its Sustainable Aging Product line, please visit https://cepham.com .